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Abstract
OBJECTIVE—To determine whether prior spontaneous (SAB) or induced (IAB) abortions, or
the inter-pregnancy interval are associated with subsequent adverse pregnancy outcomes in
nulliparous women.
METHODS—We performed a secondary analysis of data collected from nulliparous women
enrolled in a completed trial of vitamins C and E or placebo for preeclampsia prevention. Adjusted
odds ratios for maternal and fetal outcomes were determined for nulliparous women with prior
SABs and IABs as compared to primigravid participants.
RESULTS—Compared with primigravidas, women with one prior SAB were at increased risk for
perinatal death (OR 1.5; 95% CI 1.1–2.3) in subsequent pregnancies. Two or more SABs were
associated with an increased risk for spontaneous preterm birth (OR 2.6, 95% CI 1.7–4.0), preterm
PROM (OR 2.9, 95% CI 1.6–5.3) and perinatal death (OR 2.8, 95% CI 1.5–5.3). Women with one
previous IAB had higher rates of spontaneous preterm birth (OR 1.4, 95% CI 1.0–1.9) and preterm
PROM (OR 2.0, 95% CI 1.4–3.0). An inter-pregnancy interval less than 6 months after SAB was
not associated with adverse outcomes.
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CONCLUSION—Nulliparous women with a history of SAB or IAB, especially multiple SABs,
are at increased risk for adverse pregnancy outcomes.
INTRODUCTION
Spontaneous pregnancy loss before 20 weeks gestation is known to affect 12–14% of
pregnant women (1,2). About 1.2 million pregnancies in the United States are medically or
surgically terminated each year, corresponding to 22.4 percent of pregnancies (3), with 40%
performed in nulliparous women. Both spontaneous and induced abortions have been
associated with adverse pregnancy outcome in a subsequent pregnancy (4–10), including
preterm birth (PTB), pre-eclampsia, low birthweight and operative delivery. The relation of
future pregnancy outcomes to the duration of the conception-free interval following a
spontaneous or induced abortion is uncertain (11). Improved outcomes with longer intervals
were observed in a retrospective study (7), but spontaneous abortions (SABs) and induced
abortions (IABs) were not separately analyzed. Some studies showed no effect of the inter-
pregnancy interval (12, 13), while others found more favorable outcomes with shorter
intervals (14,15). Our hypotheses were that a history of spontaneous or induced abortion is
associated with adverse pregnancy outcomes in a subsequent pregnancy, and that among




We analyzed outcome data of low-risk nulliparous women enrolled in the Eunice Kennedy
Shriver National Institutes of Health and Human Development Maternal-Fetal Medicine
Units Network randomized controlled trial of vitamins C and E versus placebo daily from 9–
16 weeks’ gestation until delivery(16). Recruitment was conducted from July 2003 through
February 2008 at 16 clinical centers. Briefly, pregnant women with a viable singleton fetus
between 9 weeks 0 days and 16 weeks 6 days gestation were eligible for the primary study.
Women with a previous pregnancy that lasted beyond 19 weeks 6 days were ineligible.
Women with a systolic blood pressure 135 mm Hg or higher, diastolic blood pressure 85
mm Hg or higher, proteinuria, or those who were taking or had taken antihypertensive
medication were also excluded. Women were also excluded if they had pre-gestational
diabetes, were taking anti-platelet drugs or non- steroidal anti-inflammatory agents, had
uterine bleeding within the week before recruitment, uterine malformation, serious medical
condition, known fetal anomaly or aneuploidy, in vitro fertilization resulting in the current
pregnancy, or abuse of illicit drugs or alcohol. Participants were followed until delivery and
their outcomes were determined prospectively.
Study groups
As part of the primary study enrollment, women were asked about past pregnancies in detail
including, month, year and outcome. Participants were specifically asked whether the
pregnancy ended as a result of spontaneous miscarriage, induced abortion, ectopic or molar
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pregnancy. Patients who were not fluent in English were enrolled by someone fluent in their
language and signed a consent form in their language.
For this secondary analysis, participants were categorized to one of three groups: those with
no prior pregnancy (primigravid), those with one or more SABs, and those with one or more
IABs. Women with a prior ectopic pregnancy, molar pregnancy, or with history of both
spontaneous and induced abortions were excluded. Outcomes were analyzed based on the
number of prior abortions (one versus more than one).
The effect of inter-pregnancy interval on pregnancy outcomes was analyzed in women with
a history of one SAB or one IAB. The inter-pregnancy interval was defined as the time
elapsed from date of abortion to last menstrual period of the index pregnancy. Three inter-
pregnancy intervals were analyzed: less than 6 months (<183 days), 6–12 months (183–364
days) and greater than 12 months (≥365 days). These intervals were chosen based on those
reported in prior studies (7, 15).
Study Outcomes
Study outcomes were collected by trained research staff following pre-specified definitions.
Data were collected in a uniform manner across all the study sites on pre-specified forms.
Maternal outcomes analyzed were spontaneous preterm birth, indicated preterm birth,
preterm PROM and preeclampsia. Spontaneous PTB was defined as a birth occurring at less
than 37 weeks 0 days gestation as a result of spontaneous onset of labor or preterm PROM,
excluding pregnancies that were lost as a result of SAB or IAB prior to 20 weeks 0 days.
PTBs occurring secondary to maternal or fetal indications (i.e., indicated preterm deliveries)
were reported separately from spontaneous PTBs. Fetal and neonatal outcomes included
fetal or neonatal death, birthweight less than the 5th percentile for gestational age adjusted
by sex and race (17), and admission to the neonatal intensive care unit.
Statistical Analyses
Categorical variables were compared using the chi-square test and continuous variables
using the Kruskal-Wallis test. Multivariable logistic regression analysis was used to
calculate odds ratios (OR) and included maternal age, race, education, smoking, marital
status, BMI at enrollment, and whether they received placebo or vitamins C and E in the
randomized trial. A nominal p value less than 0.05 was considered to indicate statistical
significance and no adjustments were made for multiple comparisons. Analyses were
performed using SAS software (Cary, NC). The original trial had been approved by the
institutional review board at each clinical site and the data coordinating center.
RESULTS
Study participants
In the original study (16), 10154 women underwent randomization and 183 were lost to
follow up. One subject had data removed at her request and another had data removed at the
IRB’s request. Therefore, outcomes were available for 9969 nulliparas enrolled in the
randomized trial. We excluded 231 women: three were multiparous and erroneously
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enrolled, one died prior to delivery, 88 had a history of ectopic pregnancy, and 139 had a
history of both spontaneous and induced abortions. The analyzed groups consisted of 7681
primigravid women, 1060 women with a history of one SAB and 180 women with a history
of two or more SABs. There were 642 women with a history of one IAB and 175 subjects
with a history of two or more IABs. The demographics are listed in Table 1.
Women with prior SAB
Compared with primigravid women, women with a history of one SAB were at increased
risk for fetal or neonatal death (adj. OR 1.5; 95% CI 1.1–2.3) (Table 2). Women with 2 or
more SABs were at increased risk for spontaneous PTB (adj. OR 2.6, 95% CI 1.7–4.0),
preterm PROM (adj. OR 2.9, 95% CI 1.6–5.3), perinatal death (adj. OR 2.8, 95% CI 1.5–
5.3), and birthweight less than the 5th percentile (adj. OR 2.2, 95% CI 1.3–3.7). The risk for
pre-eclampsia and neonatal intensive care admissions were not different in women with a
history of one SAB or two or more SABs compared with primigravid women.
Women with prior IAB
Compared with primigravidas, women with a history of one IAB were at increased risk for
spontaneous PTB (adj. OR 1.4, 95% CI 1.0–1.9) and preterm PROM (adj. OR 2.0, 95% CI
1.4–3.0). These risks were not significantly increased in women with two or more IABs.
Women with a history of 2 or more IABs had a lower risk of neonatal birthweight less than
the 5th percentile (adj. OR 0.2, 95% CI 0.1–1.0). There was no significant difference in the
risk for pre-eclampsia, fetal or neonatal death or neonatal intensive care admissions
compared to primigravid women (Table 3).
Effect of inter-pregnancy interval
Of the 1060 women with a history of one SAB, the inter-pregnancy interval could be
determined in 1040. There were 395 women with a SAB-to-pregnancy interval of less than 6
months, 216 with an interval of 6–12 months and 429 with an interval greater than 12
months. Women in the 6–12 months group were at higher risk for preterm PROM (adj. OR
3.7, 95% CI 1.3–10.3) compared to women with an interval less than 6 months. There was
no statistically significant difference in any of the other outcomes compared to women with
an interval less than 6 months (Table 4).
In women with a history of a single IAB, inter-pregnancy interval could be determined in
631; 61 women had an IAB-to-pregnancy interval of less than 6 months, 64 had an interval
of 6–12 months and 506 had an interval greater than 12 months. There was no statistically
significant difference in any of the other outcomes between the groups (data not shown).
COMMENT
Our secondary analysis identified an increased risk of adverse pregnancy outcomes in low
risk women with a history of either spontaneous or induced abortion. A history of one SAB
is associated with an increased risk of perinatal death in a subsequent pregnancy. A history
of two or more SABs was associated with an increased risk of PTB, perinatal death, and
birthweight less than the 5th percentile compared to primigravid women. These findings are
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consistent with previous reports, and raise new questions about pathways that might explain
the observed associations.
Bhattacharya et al. (5) found an increased risk of pregnancy complications in women with
one prior miscarriage compared to nulliparous women. Hammoud et al. (18) also noted a
small increased risk (odds ratio of 1.13) of PTB and PPROM in women with a history of one
miscarriage. Our findings are consistent with other studies showing adverse outcomes with
increasing number of miscarriages (18–20). The association between SAB and subsequent
PTB was also confirmed in a recent meta-analysis (10).
Moreover, the results of our study are consistent with the findings of others reporting an
increased risk of adverse outcomes in women with a prior IAB (4,10, 21–24). Chen et al
found lower odds for preterm delivery in women with one mifepristone abortion compared
with women with no abortion (25). Reasons for the association between both spontaneous
and induced abortion and subsequent preterm birth are unclear. Women experiencing
spontaneous and induced abortion may share risk factors for preterm birth that are currently
unknown, or may acquire risk for subsequent preterm birth via the medical care they
received that might alter endometrial environment, e.g., antibiotic prophylaxis, duration of
cervical dilation, or uterine curettage.
If uterine instrumentation is the common exposure, it is interesting to note that women
exposed to fertility evaluation have also been reported to have an increased risk of
subsequent preterm birth (26). In our study we do not have data on medical vs. surgical
terminations. Unlike multiple SABs, we did not find a statistically significant association
between multiple IABs and PTBs or PPROM, although our ability to detect this association
may have been limited by our sample size.
Studies examining the association of SAB or IAB with hypertension and pre-eclampsia in a
subsequent pregnancy have reported conflicting results (27–31). SAB and IAB were found
to be associated with reduced pre-eclampsia risk in some studies (27, 28, 30), but not others
(30, 32). Certain studies have shown this association to be dependent on timing of abortion
(33) or the woman’s parity (28). We did not find an association between prior SAB or IAB
and pre-eclampsia. However, our study analyzed women who had no history of hypertension
or proteinuria, factors known to be related to subsequent pre-eclampsia. While this may
create a selection bias, the advantage to this exclusion is determining the association of prior
SAB or IAB with pre-eclampsia without the confounding effects of hypertensive disorders.
Women with two or more IABs had a reduced risk of SGA infants. Chen et al. (25) reported
slightly higher birth weight following mifepristone-induced abortion. Nulliparity is a risk
factor for SGA (34) compared to multiparous women. It is possible that the reduced risk for
SGA in women with multiple IABs is related to their multigravid status.
The effect of inter-pregnancy interval on pregnancy outcomes following a miscarriage has
been controversial (11). A large retrospective study (7) from South America showed
improved outcomes with longer intervals, however SABs and IABs were not separately
analyzed and the study included multiparous women. In another study evaluating inter-
pregnancy interval after SAB, Goldstein et al found no significant differences in outcomes
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between the immediate or delayed conception groups, however their study population
consisted of 64 participants (12). In contrast, a large population-based retrospective study
examining pregnancy records in Scotland from 1981 to 2000 found better pregnancy
outcomes in nulliparous women who conceived within 6 months of a spontaneous abortion
(15).
The SAB sample size for our study yields a power of 0.75 for two sided alpha of 0.05 to
detect the PTB rate difference reported previously (7). In the SAB group our study found
higher risk for preterm PROM in women whose inter-pregnancy interval was 6–12 months
as compared to those with an interval of less than 6 months but the potential biological
mechanisms of this observation are unknown. Otherwise, there was no statistically
significant association between inter-pregnancy interval and adverse outcomes. Our results
do not support recommending a waiting period following miscarriage. One limitation of our
study and all other studies addressing inter-pregnancy interval following miscarriage is lack
of knowledge whether the women had intentionally waited beyond 6 months or had
decreased fertility or other factors compared to those that conceived sooner. Our findings,
along those of other investigations, underscore the need for a prospective study to address
this question.
Data on the previous type and number of abortions were collected by research personnel in
an interview with the study participant, and the medical records of the prior pregnancies
were not reviewed. Although abstracting data from medical records is more accurate, our
data were obtained specifically on each past pregnancy and by research personnel fluent in
the patient’s language. While under-reporting of IAB is a known limitation of surveys (35),
the net effect of under-reporting would be an apparent decrease in the risk of adverse
outcomes in the IAB group. Therefore the risk of adverse outcomes could be potentially
higher than what our data have shown.
The strengths of our study include a large cohort, low risk population and well-documented
maternal and perinatal outcomes. Additionally, because SAB and IAB data were collected
and analyzed in an identical fashion, our findings suggest that the adverse outcomes
following multiple SABs are more frequent and more severe than after IAB; in agreement
with a recent cohort study from Scotland (36). The discrepancy in outcomes following
multiple SABs versus multiple IABs suggests that adverse outcomes following multiple
spontaneous abortions are not solely related to pregnancy evacuation.
A possible limitation of our study is the lack of information on gestational age at the time of
abortion or of the surgical or medical techniques used in the termination. Higher gestational
age at the time of a SAB is associated with worse outcomes in a subsequent pregnancy (37–
38). Similarly, dilation and evacuation may be associated with worse complications than
medically induced abortion (4–25). Finally, it is possible that the multiple comparisons
performed could have resulted in spurious findings and apparent associations due to chance.
The last of these is made unlikely by the similarity of our observations to previous
observational reports.
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Our findings suggest that adverse outcomes in future pregnancies are increased in women
with a history of spontaneous or induced abortion even in the absence of medical risk
factors. These risks are higher in women with a history of two prior SABs. In contrast, there
was no clear association between inter-pregnancy interval and subsequent pregnancy
outcome. Large prospective studies specifically intended to discover linkages between
spontaneous and induced abortion with preterm parturition and other adverse outcomes are
needed to better identify risk factors for subsequent pregnancies in women with prior
abortion(s). Nonetheless, our findings may be helpful in the counseling of women with
previous spontaneous or induced abortions.
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Table 1
Demographics and Baseline Characteristics
Primigravid (N=7681) One or more SABs (N=1240) One or more IABs (N=817) P
Treatment group 0.6
 Placebo 3827 (49.8) 610 (49.2) 420 (51.4)
 Vitamins 3854 (50.2) 630 (50.8) 397 (48.6)
Tobacco use 1057 (13.8) 225 (18.1) 211 (25.8) <0.0001
Married 3370 (43.9) 556 (44.8) 233 (28.5) <0.0001
Race <0.0001
 African American 1839 (23.9) 321 (25.9) 288 (35.3)
 Hispanic 2475 (32.2) 377 (30.4) 174 (21.3)
 Caucasian/Other 3367 (43.8) 542 (43.7) 355 (43.5)
Maternal age 23.1 ± 5.0 24.5 ± 5.5 25.0 ± 5.6 <0.0001
Total years of schooling 12.7 ± 2.8 12.7 ± 2.7 13.5 ± 2.1 <0.0001
BMI at enrollment 26.1 ± 6.0 27.0 ± 6.6 26.4 ± 5.9 <0.0001
GA at enrollment (weeks) 13.4 ± 2.1 13.3 ± 2.1 13.3 ± 2.2 0.07
Data represented as N (Percent) or Mean ± S. D.
SAB=spontaneous abortion, IAB=induced abortion, BMI=body mass index, GA=gestational age
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Table 2
Multivariable analysis of maternal and fetal outcomes in subjects with history of one or multiple SABs.
Outcome Primigravid (N=7681) One SAB (N=1060) Two or More SABs (N=180)




























Data shown are number of outcomes (percent)
Odds ratio compared to the primigravid group [95% confidence interval] were calculated after adjusting for maternal age, race, education, smoking,
marital status, BMI at enrollment, and study drug (placebo or vitamin C and E). Odds ratio in bold typeface are statistically significant.
SAB=spontaneous abortion, PROM=premature rupture of membranes
*
Excludes 110 women whose current pregnancy resulted in SAB or IAB (87 primigravid, 17 one SAB, 6 two or more SABs).
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Table 3
Multivariable analysis of maternal and fetal outcomes in subjects with history of one or multiple IABs.
Outcome Primigravid (N=7681) One IAB (N=642) Two or More IABs (N=175)




























Data shown are number of outcomes (percent)
Odds ratio compared to the primigravid group [95% confidence interval] were calculated after adjusting for maternal age, race, education, smoking,
marital status, BMI at enrollment, and study drug (placebo or vitamin C and E). Odds ratio in bold typeface are statistically significant.
IAB=induced abortion, PROM=premature rupture of membranes
*
Excludes 97 women whose current pregnancy resulted in SAB or IAB (87 primigravid, 7 one IAB, 3 two or more IABs).
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Table 4
Multivariable analysis of maternal and fetal outcomes in subjects with history of one SAB based on inter-
pregnancy interval.
Outcome Less than 6 months (N=395) 6–12 months (N=216) Greater than 12 months (N=429)




























Data shown are number of outcomes (percent)
Odds ratio compared to the less than 6 months group [95% confidence interval] were calculated after adjusting for maternal age, race, education,
smoking, marital status, BMI at enrollment, and study drug (placebo or vitamin C and E). Odds ratio in bold typeface are statistically significant.
SAB=spontaneous abortion, PROM=premature rupture of membranes
*
Excludes 17 women whose current pregnancy resulted in SAB or IAB.
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